Abstract
The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.
| Original language | English |
|---|---|
| Pages (from-to) | 393-399 |
| Number of pages | 7 |
| Journal | Neurological Sciences |
| Volume | 32 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2011 |
Fingerprint
Keywords
- Cerebral oligometastases
- Hypofractionated stereotactic radiotherapy
- Whole-brain radiotherapy
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
Cite this
Hypofractionated stereotactic radiotherapy for oligometastases in the brain : A single-institution experience. / Marchetti, Marcello; Milanesi, Ida; Falcone, Chiara; De Santis, Michela; Fumagalli, Luisa; Brait, Lorenzo; Bianchi, Livia; Fariselli, Laura.
In: Neurological Sciences, Vol. 32, No. 3, 06.2011, p. 393-399.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hypofractionated stereotactic radiotherapy for oligometastases in the brain
T2 - A single-institution experience
AU - Marchetti, Marcello
AU - Milanesi, Ida
AU - Falcone, Chiara
AU - De Santis, Michela
AU - Fumagalli, Luisa
AU - Brait, Lorenzo
AU - Bianchi, Livia
AU - Fariselli, Laura
PY - 2011/6
Y1 - 2011/6
N2 - The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.
AB - The treatment of brain metastases is changing. Many different radiotherapy options are now available and under clinical evaluation. As part of this effort, we retrospectively evaluated the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in patients with up to three brain metastases. Sixty-five patients with 81 lesions were treated with hypofractionated radiotherapy. Median dose was 24 Gy in three fractions. Median followup was 24.6 months. Actuarial tumour control was 75 and 45% at 9 months and 24 months after treatment, respectively. Median survival time was 7.5 months, and 32% of the patients died from brain tumour progression. Actuarial overall survival was 75% at 3 months and 25% at 12 months. Recursive partitioning analysis class was the only significant prognostic factor. Neoadjuvant wholebrain radiotherapy (in 29 patients) had no impact on survival or local control. Neurological status improved in 42 patients (65%). Adverse events were rare and usually mild. This experience suggests HSRT should be considered as an alternative approach in the treatment of one to three metastatic lesions in selected patients.
KW - Cerebral oligometastases
KW - Hypofractionated stereotactic radiotherapy
KW - Whole-brain radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=79960175293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960175293&partnerID=8YFLogxK
U2 - 10.1007/s10072-010-0473-4
DO - 10.1007/s10072-010-0473-4
M3 - Article
C2 - 21234772
AN - SCOPUS:79960175293
VL - 32
SP - 393
EP - 399
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 3
ER -